SCHEMBL6281896

SCHEMBL6281896

CCCCC(O)CC(O)CCC

nearest known ligand 0.41

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
GPR84 Q9NQS5 5/20 0.41
FFAR4 Q5NUL3 1/20 0.40
FFAR1 O14842 1/20 0.40
NFKB1 P19838 1/20 0.39
ALDH1A1 P00352 1/20 0.39
DNM1 Q05193 2/20 0.38
FDPS P14324 1/20 0.37
CA2 P00918 1/20 0.36
MAPK1 P28482 1/20 0.36
PSMD14 O00487 2/20 0.35
PLA2G1B P04054 2/20 0.35
MMP2 P08253 2/20 0.35
ATG4B Q9Y4P1 2/20 0.35
HSP90AA1 P07900 1/20 0.35
RAD52 P43351 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28575324 1.00 GPR84 (0.41) GPR84FFAR4FFAR1NFKB1ALDH1A1
SCHEMBL15247077 0.97 GPR84 (0.40) GPR84FFAR4FFAR1NFKB1ALDH1A1
SCHEMBL4378460 0.94 GPR84 (0.44) GPR84FFAR4FFAR1NFKB1ALDH1A1
SCHEMBL14533072 0.94 GPR84 (0.44) GPR84FFAR4FFAR1NFKB1ALDH1A1
SCHEMBL14533070 0.94 GPR84 (0.44) GPR84FFAR4FFAR1NFKB1ALDH1A1
SCHEMBL11742369 0.93 ALDH1A1 (0.39) GPR84FFAR4FFAR1NFKB1ALDH1A1
SCHEMBL3687762 0.92 GPR84 (0.50) GPR84FFAR4FFAR1NFKB1PSMD14
SCHEMBL30787445 0.90 GPR84 (0.54) GPR84FFAR4FFAR1NFKB1PSMD14
SCHEMBL30787144 0.90 GPR84 (0.54) GPR84FFAR4FFAR1NFKB1PSMD14
SCHEMBL30787281 0.90 GPR84 (0.54) GPR84FFAR4FFAR1NFKB1PSMD14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6899753-B2 Highly bleed-alleviating ink composition BENQ CORPORATION (TW) 2005-05-31 US claimed
US-20030037700-A1 Highly bleed-alleviating ink composition MIND FUSION, LLC 2003-02-27 US claimed
CN-112119137-A Multilayer pressure sensitive adhesive assembly 3M创新有限公司 2020-12-22 CN disclosed
EP-2700636-B1 PROCESS FOR PREPARING EPISULFIDE COMPOUNDS ASAHI CHEMICAL IND (JP) 2017-08-02 EP disclosed
CN-106831862-A Axial chirality monophosphorus ligand of one class chirality bridging and preparation method thereof 中山大学 2017-06-13 CN disclosed
US-9359324-B2 Process for preparing episulfide compounds ASAHI KASEI CHEMICALS CORPORATION (JP) 2016-06-07 US disclosed
CN-103476764-B Process for producing episulfide compound ASAHI KASEI KABUSHIKI KAISHA (JP) 2016-05-25 CN disclosed
US-20150197501-A1 Process for Preparing Episulfide Compounds ASAHI KASEI CHEMICALS CORPORATION (JP) 2015-07-16 US disclosed
US-9051293-B2 Process for preparing episulfide compounds ASAHI KASEI CHEMICALS CORPORATION (JP) 2015-06-09 US disclosed
CN-104610222-A Process for preparing episulfide compounds ASAHI KASEI CHEMICALS CORP 2015-05-13 CN disclosed
US-20140107350-A1 Process for Preparing Episulfide Compounds ASAHI KASEI CHEMICALS CORPORATION (JP) 2014-04-17 US disclosed
EP-2700636-A1 PROCESS FOR PREPARING EPISULFIDE COMPOUNDS Asahi Kasei Chemicals Corporation (JP) 2014-02-26 EP disclosed
CN-101519552-B Method for preparing inkjet water-soluble ink containing noble metal nano particles CHINESE ACAD INST CHEMISTRY 2011-08-24 CN disclosed
CN-101519552-A Method for preparing inkjet water-soluble ink containing noble metal nano particles CHINESE ACAD INST CHEMISTRY 2009-09-02 CN disclosed
US-6899753-B2 Highly bleed-alleviating ink composition BENQ CORPORATION (TW) 2005-05-31 US disclosed
CN-1401710-A Ink composition with high ink bleeding prevention BENQ CORP (CN) 2003-03-12 CN disclosed
US-20030037700-A1 Highly bleed-alleviating ink composition MIND FUSION, LLC 2003-02-27 US disclosed
US-6376691-B1 Metal organic precursors for transparent metal oxide thin films and method of making same SYMETRIX CORPORATION 2002-04-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150197501-A1 Process for Preparing Episulfide Compounds TST, EPHX2, STS GPR84 3934/4885FFAR4 4324/4885FFAR1 4701/4885
US-20140107350-A1 Process for Preparing Episulfide Compounds TST, EPHX2, STS GPR84 3934/4885FFAR4 4324/4885FFAR1 4701/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.